Erech Finance Cahalacha Ltd Total Liabilities
Erech Finance Cahalacha Ltd total liabilities. Based on the latest financial reports, Erech Finance Cahalacha Ltd (EFNC) has total liabilities worth ILA19.14 Million ILA (≈ $51.31K USD) as of December 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check EFNC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Erech Finance Cahalacha Ltd (2014–2023)
Total liabilities of Erech Finance Cahalacha Ltd from 2014 to 2023. This chart illustrates how Erech Finance Cahalacha Ltd's total liabilities have evolved over time, based on quarterly financial data.
Erech Finance Cahalacha Ltd Competitors by Total Liabilities
The table below lists competitors of Erech Finance Cahalacha Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Foresight Ventures VCT plc
LSE:FVEN
|
UK | GBX2.04 Million |
|
Wingara AG Ltd
AU:WNR
|
Australia | AU$1.31 Million |
|
Aranjin Resources Ltd
V:ARJN
|
Canada | CA$1.30 Million |
|
Prominence Energy Limited
F:RSX
|
Germany | €517.52K |
|
Duros S.A.
AT:DUR
|
Greece | €9.43 Million |
|
Rapid Nutrition PLC
PA:ALRPD
|
France | €403.84K |
|
OSX Brasil S.A
SA:OSXB3
|
Brazil | R$10.90 Billion |
|
TH1NG AB
ST:TH1NG
|
Sweden | Skr30.89 Million |
Liability Composition Analysis (2014–2023)
This chart breaks down Erech Finance Cahalacha Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see EFNC current and non-current assets.
Liquidity & Leverage Metrics
Erech Finance Cahalacha Ltd Total Liabilities Ratios Explained
Erech Finance Cahalacha Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.82 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Erech Finance Cahalacha Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Erech Finance Cahalacha Ltd (2014–2023)
The table below shows the annual total liabilities of Erech Finance Cahalacha Ltd from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | ILA19.14 Million ≈ $51.31K |
-53.07% |
| 2022-12-31 | ILA40.78 Million ≈ $109.34K |
-20.63% |
| 2021-12-31 | ILA51.38 Million ≈ $137.75K |
+18.93% |
| 2020-12-31 | ILA43.20 Million ≈ $115.82K |
-12.64% |
| 2019-12-31 | ILA49.45 Million ≈ $132.58K |
+20.51% |
| 2018-12-31 | ILA41.04 Million ≈ $110.02K |
+2397.63% |
| 2017-12-31 | ILA1.64 Million ≈ $4.40K |
-82.03% |
| 2016-12-31 | ILA9.14 Million ≈ $24.51K |
+9.77% |
| 2015-12-31 | ILA8.33 Million ≈ $22.33K |
-4.82% |
| 2014-12-31 | ILA8.75 Million ≈ $23.46K |
-- |
About Erech Finance Cahalacha Ltd
Erech Finance Cahalacha Ltd, together with its subsidiaries, provides loans and credit services to small and medium sized enterprises, associations, and private borrowers in Israel. It is also involved in the development of biomed-drugs in the areas of juvenile diabetes and cancer. The company was founded in 1998 and is based in Jerusalem, Israel.